Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Processa Pharmaceuticals, Inc. (PCSA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/17/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer HANOVER, MD, August 8, 2023 — Processa Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company focusing on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for patients suffering from cancer, announces today that industry veteran George Ng has been appointed to serve as the Company’ s Chief Executive Officer and as a Board Director as of August 8, 2023. Dr. David Young will focus his efforts on the development of the Next Generation Chemotherapy drugs as President of Research and Development and as a board member. “We are thrilled to have George assume the leadership of our management team. His extensive managerial experience and proficien..."
06/29/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to the fourth AMENDED AND RESTATED certificate of incorporation of Processa pharmaceuticals, inc. Processa Pharmaceuticals, Inc. , a corporation organized and existing under the General Corporation Law of the State of Delaware , hereby certifies as follows: 1. This Certificate of Amendment amends the provisions of the Corporation’ s Fourth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on September 27, 2017, as amended on October 23, 2017, August 8, 2019, December 23, 2019, June 25, 2020, and January 1, 2022 . 2. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the DGCL setting forth a proposed amendment to the Certificate of Incorporation and declaring s..."
05/24/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
05/18/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative HANOVER, MD, May 18, 2023 – Processa Pharmaceuticals, Inc. today announces it has received guidance from the U.S. Food and Drug Administration regarding the Company’ s next trial for Next Generation Chemotherapy-Capecitabine . The trial for NGC-Cap, the combination of PCS6422 and capecitabine, will be a Phase 2 safety-efficacy trial in colorectal cancer patients following the principles of FDA’ s Project Optimus Oncology Initiative, the recent FDA recommendation on how oncology drugs are to be developed going forward."
05/05/2023 8-K Quarterly results
03/31/2023 8-K Quarterly results
03/22/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
02/13/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
01/09/2023 8-K Quarterly results
12/22/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
11/04/2022 8-K Quarterly results
09/06/2022 8-K Regulation FD Disclosure  Interactive Data
08/12/2022 8-K Quarterly results
Docs: "[email protected]"
08/04/2022 8-K Quarterly results
07/25/2022 8-K Quarterly results
07/14/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
03/24/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "ATTORNEYS AT LAW",
"EXHIBITS",
"Information About The Investor Furnished To The Company By The Investor Expressly For Use In Connection With Each Registration Statement and Prospectus Supplement Information With Respect to Lincoln Park Capital As of the date of the Purchase Agreement, Lincoln Park Capital Fund, LLC, beneficially owned 123,609 shares of our common stock. Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, the manager of Lincoln Park Capital Fund, LLC, are deemed to be beneficial owners of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and investment power over the shares being offered under the prospectus supplement filed with the SEC in connection with the transactions contemplated under the Purch..."
03/17/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/26/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Processa Pharmaceuticals CEO Dr. David Young Issues Letter to Shareholders Providing Outlook for 2022 HANOVER, MD., January 26, 2022 — Processa Pharmaceuticals, Inc. , a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’ s survival and/or quality of life, today released the following letter to shareholders from its Chief Executive Officer Dr. David Young. Dear Fellow Shareholder: As we start a new year, I want to thank you for your support and take this opportunity to share our accomplishments in 2021 and our planned path forward. We believe 2022 will be a transformative year for Processa as our multi-asset pipeline continues to mature and we achieve important clinical milestones. Our pipeline i..."
01/06/2022 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT TO THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF PROCESSA PHARMACEUTICALS, INC. Processa Pharmaceuticals, Inc. , a corporation organized and existing under the General Corporation Law of the State of Delaware , hereby certifies as follows: 1. This Certificate of Amendment amends the provisions of the Corporation’ s Fourth Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on September 27, 2017, as amended on October 23, 2017, August 12, 2019, December 19, 2019 and June 25, 2020 . 2. The Board of Directors of the Corporation has duly adopted a resolution pursuant to Section 242 of the DGCL setting forth a proposed amendment to the Certificate of Incorporation and declaring said amendment to ..."
11/05/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
09/20/2021 8-K Quarterly results
08/20/2021 8-K Quarterly results
08/13/2021 8-K Quarterly results
07/29/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "July 2021 Corporate Presentation"
07/15/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Processa Pharmaceuticals Investor Presentation dated July 2021"
06/17/2021 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "License Agreement",
"PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy